Avalo Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Avalo Therapeutics, Inc.
Neumora’s once-daily oral kappa opioid receptor (KOR) antagonist navacaprant succeeded in a Phase II trial and will move into the first of three Phase III studies soon, with a US filing targeted for 2025.
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- Aevi Genomic Medicine, Inc.
- Cerecor Inc.
- Ichorion Therapeutics, Inc.
- Trx Pharmaceuticals, LLC
- Zylera Phamaceuticals, LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.